Try our Advanced Search for more refined results

Effexor Ruling Gives Plaintiffs Path Against No-AG Deals

By Melissa Lipman (October 8, 2014, 9:44 PM EDT) -- A district court's Monday ruling that no-authorized-generic agreements between pharmaceutical companies don't have to include cash to count as pay-for-delay settlements under federal antitrust law offers a possible roadmap for pursuing similar claims, but attorneys say the future of such deals will remain hazy until appeals courts tackle the issue....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!